Table 3.
Association of visceral fat area with kidney function decline stratified by baseline CKD
| Variable | N | ΔeGFR>30% | Unadjusted OR (95% CI) | Model 1a OR (95% CI) | Model 2b OR (95% CI) | Model 3c OR (95% CI) |
|---|---|---|---|---|---|---|
| Visceral fat (eGFR≥60 ml/min per 1.73 m2) | ||||||
| Continuous (per SD=121) | 2295 | 387 | 1.4 (1.2 to 1.5) | 1.4 (1.2 to 1.5) | 1.3 (1.1 to 1.4) | 1.3 (1.1 to 1.4) |
| Quartiles | ||||||
| <196 | 584 | 79 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| 196–267 | 591 | 78 | 0.9 (0.7 to 1.3) | 1.0 (0.7 to 1.3) | 0.9 (0.6 to 1.3) | 0.9 (0.6 to 1.2) |
| 268–357 | 572 | 102 | 1.4 (1.0 to 1.9) | 1.4 (1.0 to 1.9) | 1.2 (0.9 to 1.7) | 1.2 (0.9 to 1.7) |
| >357 | 548 | 128 | 2.0 (1.4 to 2.7) | 2.0 (1.5 to 2.8) | 1.6 (1.2 to 2.2) | 1.6 (1.1 to 2.3) |
| Visceral fat (eGFR<60 ml/min per 1.73 m2) | ||||||
| Continuous (per SD=67) | 194 | 47 | 0.8 (0.6 to 1.2) | 0.9 (0.6 to 1.2) | 0.8 (0.5 to 1.2) | 0.7 (0.5 to 1.1) |
| Quartiles | ||||||
| <94 | 34 | 9 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| 94–132 | 35 | 11 | 1.4 (0.5 to 4.0) | 1.7 (0.6 to 5.3) | 1.0 (0.8 to 12.0) | 2.8 (0.7 to 11.8) |
| 133–181 | 53 | 13 | 1.0 (0.4 to 2.8) | 1.3 (0.4 to 3.8) | 1.2 (0.5 to 5.9) | 1.4 (0.4 to 5.8) |
| >181 | 72 | 14 | 0.7 (0.2 to 1.8) | 0.8 (0.3 to 2.5) | 1.4 (0.2 to 3.2) | 0.6 (0.1 to 2.6) |
Kidney function decline defined as eGFR-cystatin C decline >30%. OR, odds ratio; 95% CI, 95% confidence interval; ref, reference.
a
Adjusted for age, sex, race, and site.
b
Further adjusted for diabetes mellitus, systolic blood pressure, hypertension meds, albumin-to-creatinine ratio.
c
Further adjusted smoking, LDL cholesterol, HDL cholesterol, oral estrogen, prevalent coronary heart disease and prevalent heart failure.